Neoadjuvant Chemotherapy in Upper Tract Urothelial Carcinoma : a Retrospective Multicentric Study.
Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Jan 3, 2023
Trial Information
Current as of May 27, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patients over 18 years of age
- • 2. Male or female
- • 3. Upper excretory tract tumors
- • 4. Localized or locally advanced stage (N0 to N1)
- • 5. Eligible for curative surgery
- • 6. Have received neoadjuvant or primary chemotherapy
- • 7. Neoadjuvant chemotherapy treatment received between 2010 and 2020.
- Exclusion Criteria:
- • 1. Patient's opposition to the research
- • 2. UTUC not eligible for curative surgery
- • 3. Locally advanced UTUC ≥ N2 and/or metastatic.
About Assistance Publique Hôpitaux De Paris
Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials